Collectively, these findings demonstrated that ATP11B maintained PD-L1 expression through the prevention of its lysosomal degradation mediated by CMTM6, suggesting that the aberrantly expressed ATP11B might be a potential target to combat pancreatic cancer. The gene discussed is CD274; the disease is familial pancreatic carcinoma.